Browse by ▼

Allergan, Inc.

  • Should These Drug Companies Pay a Dividend?

    By Chris Hodge - May 23, 2013 | Tickers: AGN, RDY, NVO

    Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusions about their dividend arrangements.

    Use the money to grow

    Allergan (NYSE: AGN) is a mid-size company, fairly small by pharma standards. It pays a paltry 0.2% dividend yield more »

  • Why This Stock's Crash is a Buying Opportunity

    By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

    It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

    Allergan’s Outlook

    It was almost a tale more »

  • Should We Get Bullish on This Fast Growing Healthcare Company?

    By Anh HOANG - May 10, 2013 | Tickers: AGN, JNJ, NVS

    Allergan (NYSE: AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in the middle of April 2013. However, Allergan has experienced a lot of recent volatilty, and now is near $105. The company is in the portfolio of several successful investors including Joel Greenblatt and Jim Simons. Should investors consider Allergan at its more »

  • Key Earnings this Week

    By Lee Samaha - May 2, 2013 | Tickers: AGN, FB, MAS, PFE

    It’s another big week for earnings and by now investors will have formulated a thesis on the first quarter. That thesis will be put to the test this week. In my view there are some clear signs that there was a bit of caution over discretionary spending among corporations. Will it continue?

    As the weeks go by, let's recall that companies will get a bit more data on more »

  • Scared of a Market Fall? Watch These Defensive Growth Stocks

    By Lee Samaha - April 29, 2013 | Tickers: AGN, CHD, PRGO, COO, TJX

    The market turbulence in April has left many if whether we are headed for another spring sell off. I have no opinion on this, per se, but what I do know is that it always makes sense for investors to try and be diversified. So if you are worried about the economy or just looking to create a balanced portfolio, the following stocks should be of interest.

    Defensive growth

    I more »

  • Possible Synergies in This Buyout

    By Mike Thiessen - April 4, 2013 | Tickers: AGN, OMPI, VRX

    Investors have greeted the recent announcement that Valeant Pharmaceuticals (NYSE: VRX) and Obagi Medical Products (NASDAQ: OMPI) with enthusiasm. Structured as a Valeant buyout of Obagi, the deal offers a handsome premium for the medical company and provides further evidence that the latest wave of pharmaceutical consolidation has not yet peaked. Although this transaction does not have the same heft as some of the industry's other recent high-profile mergers more »

  • Possible Synergies in This Buyout

    By Mike Thiessen - April 4, 2013 | Tickers: AGN, OMPI, VRX

    Investors are enthusiastic about the recent merger announcement between Valeant Pharmaceuticals (NYSE: VRX) and Obagi Medical Products (NASDAQ: OMPI).

    Structured as a Valeant buyout of Obagi, the deal offers a handsome premium for the medical company and provides further evidence that the latest wave of pharmaceutical consolidation has not yet peaked. Although this transaction does not have the same heft as some of the industry's other recent high-profile mergers more »

  • Why these Large-Cap Stocks Need to be Bought Right Now

    By Shweta Dubey - March 20, 2013 | Tickers: AGN, AME, AON

    As the market pushes towards new highs, it’s time to look for large-cap stocks with solid fundamentals. With a better established business presence, these companies are less prone to uncertainties. Though their business growth rate may not be too high, that is offset by their stability in profits. These stocks are beneficial for those investors who are unwilling to take high levels of risk, and also to those who more »

  • 3 Health Stocks that Look Pretty

    By Alex Bastardas - March 18, 2013 | Tickers: ALGN, AGN, CYNO

    Sales growth in the beauty, personal care, and aesthetic treatment market in the United States doubled the average consumer spending rate growth in 2011 and in 2012. This year will probably not be an exception. In today's image-driven society, people are willing to spend significant amounts of money to look their best. And it's not just women - men are also jumping on the bandwagon, and so are foreign more »

  • Invest in the Spending Trends of the Wealthy

    By Lee Samaha - March 10, 2013 | Tickers: AGN, SAM, LULU, MYGN, WFM

    I have a quick trivia question. What share of total US net worth does the bottom 60% of US citizens (ranked by net worth) hold? The answer is just 4.2%, while the top 5% of US citizens (again ranked by net worth) owns nearly 62%.

    Now consider an average superstore in an average mall (such a thing doesn’t actually exist, but assume it does), and accept that spending more »

  • Pharma Buyout With a 60% Premium

    By Mike Thiessen - February 12, 2013 | Tickers: AGN, MAPP, MRK, PFE

    Irvine, California-based healthcare company Allergan (NYSE: AGN) has announced its intention to purchase Mountain View, California-based MAP Pharmaceuticals (NASDAQ: MAPP) in a complex tender deal valued at about $960 billion. The deal will involve the purchase of all of MAP's outstanding shares. Although the deal is subject to customary closing conditions like an antitrust investigation and dual shareholder vote, it appears unlikely that any issues will arise to delay more »

  • Time to Buy These Biotechnology Companies?

    By Mohsin Saeed - February 8, 2013 | Tickers: AGN, GILD

    The earnings season is in full swing with a number of stocks moving on earnings news. Allergan Pharmaceuticals (NYSE: AGN) and Gilead Sciences (NASDAQ: GILD) have announced their quarterly results recently. Their stellar results and guidance presents a buying opportunity to investors interested in health-care stocks. I have a buy rating on both stocks and believe they have a significant upside. 

    Allergan

    Allergan announced a much anticipated earnings report for more »

  • No Sign of a Slowdown at This Recession Resistant Company

    By Lee Samaha - February 7, 2013 | Tickers: AGN, JNJ, NVO, COO, VRX

    I must confess I am finding the current market to be one of the most frustrating periods of my investing life. I’ve always liked a defensive growth stock, but nowadays they seem to be so expensive that the only thing left to do is refrain from buying and sulk in the corner for a while. However, I can’t complain too much about Allergan (NYSE: AGN), as it’s more »

  • The Key Earnings For The Week (Feb. 4)

    By Lee Samaha - February 5, 2013 | Tickers: APKT, AGN, BECN, SNY, S

    Another big week for earnings and I will try and highlight some on the more interesting results to look at. These articles are quite popular so please let me know if there are any particular companies readers want covered with write ups in the week and I’ll try and get them done. There is no fixed theme or sector prevalent in this week’s earnings however I note there more »

  • Merck Scores In The Declining OAB Therapeutics Market

    By Maxwell Fisher - February 1, 2013 | Tickers: ACT, AGN, MRK

    Merck (NYSE: MRK) has seen great news recently as the FDA approved its OTC version of Oxytrol (Oxybutynin Transdermal System) for women - also good news for roughly 20 million women suffering from OAB, or overactive bladder. The Oxytrol patch, which Merck licensed from generic pharmaceuticals manufacturer Watson Pharmaceuticals, now known as Actavis (NYSE: ACT), will soon become the first over-the-counter drug treatment for OAB on the market.

    OAB Therapeutics Market more »

  • Strong Prospects at This Recession Resistant Company

    By Lee Samaha - January 17, 2013 | Tickers: AGN, JNJ, NVS, NVO, COO

    The JP Morgan Healthcare conference is the most important event in the industries calendar and helps set the tone for the rest of the investing year. Typically the pharma/biotech companies outline the key pipeline events of the year or how they plan to expand existing product sales while the medical technology and services companies discuss their prospects for the coming year. I thought I’d help investors compress their more »

  • Dermatology Market Movers Create New Investment Opportunities

    By Jordo Bivona - December 14, 2012 | Tickers: AGN, MRX, VRX

    Valeant (NYSE: VRX) is one step closer to acquiring Medicis (NYSE: MRX) with the U.S. Federal Trade Commission granting the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976. Valeant had announced its intention to acquire the specialty pharmaceutical company in September 2012, and the deal is expected to be worth approximately $2.6 billion. Medicis is engaged in the development and marketing of more »

  • This Health Care Play Has Strong Growth Prospects

    By Lee Samaha - December 13, 2012 | Tickers: AGN, JNJ, NVS, COO

    One of the things that I love about investing is coming across a company like Cooper Companies (NYSE: COO). It is exactly the sort of stock that-if told about it now- would leave most investors saying ‘of course!  But why didn’t I hear about it before when it was a great value and it made this big move?’

    While it would be easy to fall into this negative mindset more »

  • 5 Stocks Loved By This Three Billion Dollar Man

    By Meena Krishnamsetty - November 30, 2012 | Tickers: ANF, AGN, BCR, CAH, TIF

    Paul Tudor Jones founded Tudor Investment in 1980 and has a net worth over $3 billion. His fund focuses on short term trading and charges a fee that is above industry standards, charging a 4% management fee and 23% performance fee, compared to the standard 2-and-20 structure. Tudor recently filed its 13F with the SEC, which reveals public equity holdings of the firm as of the end of the third more »

  • Why Investors Will Disagree over These Stocks

    By Lee Samaha - November 28, 2012 | Tickers: AGN, ADSK, CSCO, INTC, WAB

    I’ve been meaning to write this article for a while now because I think it’s the sort of subject little discussed in mainstream journalism. Essentially, most investment journalism focuses on buying or selling this stock or other with a forthright opinion expressed either way. I understand why this formula works (not least because readers want this), but there is usually very little discourse over how or where the more »

  • Page 1 of 2